Merck & Co., Inc. (MSD; NYSE: MRK) announced that the European Commission (EC) has approved KEYTRUDA (pembrolizumab) in combination with Padcev (enfortumab vedotin‑ejfv) as neoadjuvant treatment, continued after radical cystectomy as adjuvant treatment, for adults with resectable muscle‑invasive bladder cancer (MIBC). The approval also covers KEYTRUDA SC (known as KEYTRUDA QLEX in the US) and marks the first and only PD‑1 inhibitor plus ADC regimen available for patients with MIBC regardless of cisplatin eligibility in the EU.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | European Commission (EU) |
| Approval Type | Perioperative (neoadjuvant → radical cystectomy → adjuvant) |
| Regimen | KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin‑ejfv); also covers KEYTRUDA SC (KEYTRUDA QLEX in the US) |
| Indication | Adults with resectable muscle‑invasive bladder cancer (MIBC) |
| Approval Date | 21 Oct 2026 |
| Distinction | First and only PD‑1 inhibitor + ADC regimen for MIBC in the EU, regardless of cisplatin eligibility |
| Pivotal Trial | Phase 3 KEYNOTE‑B15 (EV‑304) |
| Prior Approval | US FDA approved the same perioperative MIBC regimen in July 2026 |
Drug Profile & Mechanism of Action
- KEYTRUDA (pembrolizumab): An anti‑programmed death receptor‑1 (PD‑1) immunotherapy that restores anti‑tumor immune surveillance; Merck’s flagship oncology franchise.
- Padcev (enfortumab vedotin‑ejfv): An antibody‑drug conjugate (ADC) targeted against Nectin‑4, developed by Seagen and Astellas, delivering cytotoxic payload directly to tumor cells.
- Combination Rationale: Pairing a PD‑1 checkpoint inhibitor with a Nectin‑4‑directed ADC unites immune activation with targeted payload delivery in the perioperative setting – a dual‑modality strategy aimed at eradicating micrometastatic disease around surgery.
- Formulation Flexibility: EU approval extends to KEYTRUDA SC, offering a subcutaneous administration option alongside the intravenous formulation.
Clinical Evidence – Phase 3 KEYNOTE‑B15 (EV‑304)
| Endpoint | Result (KEYTRUDA + Padcev + Surgery) | Comparator (Neoadjuvant Gemcitabine + Cisplatin + Surgery) | Relative Benefit |
|---|---|---|---|
| Event‑Free Survival (EFS) | Risk of EFS events reduced by 47% | Standard neoadjuvant chemotherapy | 47% risk reduction |
| Overall Survival (OS) | Risk of death reduced by 35% | Standard neoadjuvant chemotherapy | 35% risk reduction |
| Pathologic Complete Response (pCR) | 55.8% | 32.5% | +23.3 percentage points |
The approval is based on the Phase 3 KEYNOTE‑B15 trial (also known as EV‑304), which evaluated perioperative KEYTRUDA in combination with Padcev and surgery versus neoadjuvant chemotherapy (gemcitabine plus cisplatin) and surgery in patients with previously untreated MIBC eligible for cisplatin‑based chemotherapy. The study demonstrated that the combination significantly improved EFS, OS, and pCR versus the chemotherapy standard of care.
Market Impact & Outlook
- New Perioperative Standard: With both FDA (July 2026) and now EC approval, KEYTRUDA + Padcev becomes the leading perioperative immunotherapy‑ADC regimen for MIBC across the world’s two largest pharmaceutical markets.
- Cisplatin‑Ineligible Access: As the first and only PD‑1 + ADC regimen available regardless of cisplatin eligibility in the EU, the approval extends treatment options to a substantial MIBC population historically excluded from cisplatin‑based neoadjuvant chemotherapy.
- Franchise Expansion: The perioperative MIBC indication deepens KEYTRUDA’s early‑disease oncology portfolio, supporting the franchise beyond its established metastatic settings.
- Ecosystem Partners: Padcev’s role underscores the strategic value of the Seagen–Astellas ADC platform within combination oncology regimens.
- Next Steps: EU member‑state reimbursement and formulary uptake; additional regulatory filings and trial readouts in the perioperative bladder‑cancer setting were not disclosed beyond this announcement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Merck’s KEYTRUDA plus Padcev perioperative MIBC franchise, including regulatory expansion, clinical outcomes, and commercial adoption. Actual results may differ materially due to risks including further regulatory actions, reimbursement decisions, real‑world clinical experience, competitive therapies, and intellectual‑property developments.-Fineline Info & Tech
